Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience

“…In a prospective randomized trial evaluating the effects of a GnRHa trigger on cycle outcomes in a non-cancer infertility population, the number of mature oocytes retrieved was significantly higher in the GnRHa group compared to the hCG group, which is consistent with our findings and those of Acevedo et al [25,28]. Erb et al noted a significantly higher number of quality embryos in the GnRHa group than in the hCG group in a retrospective donor oocyte study [26]. A potential explanation for this observation is that GnRHa trigger a more physiologic approach, similar to that of the natural mid-cycle surge.…”

“…Although our study is the largest to date in breast cancer patients to test the efficacy of GnRHa triggers in fertility preservation cycles, the success of this approach has also been demonstrated in earlier studies, in particular in oocyte donor programs [25][26][27]. In a prospective randomized trial investigating oocyte triggering agents in donor cycles, oocyte donors were randomized to receive either GnRHa or hCG.…”

Random-start gonadotropin-releasing hormone (GnRH) antagonist–treated cycles with GnRH agonist trigger for fertility preservation

“…These studies, of between 60 and 257 donors, revealed that there were no significant differences in the number of oocytes retrieved or mature oocytes in the donor, as well as no difference in pregnancy/transfer, rates of implantation, clinical pregnancy, ongoing pregnancy, and live birth between recipients receiving embryos from donors who were triggered with a GnRHa and those receiving embryos from donors triggered with hCG; however, there was a significant difference in OHSS, with a decreased risk of OHSS after GnRHa trigger (7,11,19). We had similar findings during our retrospective analysis of 32 egg donors (20). In conclusion, a GnRHa effectively triggers the final oocyte maturation in donors and significantly decreases their risk for OHSS without negatively affecting either the number of oocytes retrieved or pregnancy rates in their corresponding recipients.…”

Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles

“…Controlled ovarian stimulation using a flexible GnRH-antagonist protocol was performed as previously described elsewhere (11), with the exception that a daily 0.25 mg dose of GnRH antagonist was used. The starting dose of recombinant FSH was determined based on physician preference, taking into account the patient's age, weight, height, and ovarian reserve testing.…”